Author

Eltahir Awad Gasim Khalil

Professor of Haematology/immunohaematology, University of Khartoum, Sudan - Cited by 6,091 - Vaccines for Visceral Leishmaniasis - Latent TB infections - Immunochemotherapy for Chronic HBV

Biography

A graduate of the Faculty of Medicine, University of Khartoum. Post graduate training in hematology, United Kingdom. * Professor of Hematology & Immunology, Institute of Endemic Diseases, University of Khartoum. * Director, Field & Research Stations, Institute of Endemic Diseases, University of Khartoum. Previous Posts: * Director, Institute of Endemic Diseases, University of Khartoum * Director General, Central Laboratory, Ministry of Science & Technology, Sudan
Title
Cited by
Year
Efficacy and safety of AmBisome in combination with sodium stibogluconate or miltefosine and miltefosine monotherapy for African visceral leishmaniasis: phase II randomized trial
M Wasunna, S Njenga, M Balasegaram, N Alexander, R Omollo, ...PLoS neglected tropical diseases 10 (9), e0004880, 2016201
82
2016
Safety and effectiveness of sodium stibogluconate and paromomycin combination for the treatment of visceral leishmaniasis in eastern Africa: results from a pharmacovigilance …
R Kimutai, AM Musa, S Njoroge, R Omollo, F Alves, A Hailu, EAG Khalil, ...Clinical drug investigation 37, 259-272, 2017201
58
2017
Subtotal laparoscopic cholecystectomy influences the rate of conversion in patients with difficult laparoscopic cholecystectomy: Case series
WE Abdelrahim, KE Elsiddig, AA Wahab, M Saad, H Saeed, EAG KhalilAnnals of medicine and surgery 19, 19-22, 2017201
29
2017
Safety and immunogenicity of ChAd63-KH vaccine in post-kala-azar dermal leishmaniasis patients in Sudan
BM Younis, M Osman, EAG Khalil, F Santoro, S Furini, R Wiggins, ...Molecular therapy 29 (7), 2366-2377, 2021202
22
2021
Visceral leishmaniasis relapse hazard is linked to reduced miltefosine exposure in patients from Eastern Africa: a population pharmacokinetic/pharmacodynamic study
TPC Dorlo, AE Kip, BM Younis, SJ Ellis, F Alves, JH Beijnen, S Njenga, ...Journal of Antimicrobial Chemotherapy 72 (11), 3131-3140, 2017201
22
2017
Macrophage activation marker neopterin: a candidate biomarker for treatment response and relapse in visceral leishmaniasis
AE Kip, M Wasunna, F Alves, JHM Schellens, JH Beijnen, AM Musa, ...Frontiers in cellular and infection microbiology 8, 181, 181
20
2018
Surgical treatment of mucocele of the appendix: a systematic review and case report
EA Saad, EY Elsamani, WE AbdElrahim, KE Elsiddig, EAG KhalilJournal of surgical case reports 18 (6), rjy102, 181
20
2018
High altitude and pre-eclampsia: adaptation or protection
SIY Ahmed, ME Ibrahim, EAG KhalilMedical Hypotheses 104, 128-132, 2017201
16
2017
Mycobacterium tuberculosis complex lineage 3 as causative agent of pulmonary tuberculosis, eastern Sudan
YA Shuaib, EAG Khalil, LH Wieler, UE Schaible, MA Bakheit, ...Emerging infectious diseases 26 (3), 427, 2020202
16
2020
Etiological trends and patterns of antimicrobial resistance in respiratory infections
SMAZ Ahmed, SS Abdelrahman, DM Saad, IS Osman, MG Osman, ...The open microbiology journal 12, 34, 2018201
16
2018
Initial second-line drug resistance of Mycobacterium tuberculosis isolates from Sudanese retreatment-patients
MAM Adam, HMH Ali, EAG KhalilJournal of Clinical Tuberculosis and Other Mycobacterial Diseases 9, 21-23, 2017201
15
2017
Bone marrow and peripheral blood cells toxicity of a single 2.0 Gy Cobalt60 ionizing radiation: An animal model
S Akeem, O Lukman, K Eltahir, O Fatai, B Abiola, O KhadijatEthiopian Journal of Health Sciences 29 (2), 2019201
14
2019
Blood parasite load as an early marker to predict treatment response in visceral leishmaniasis in Eastern Africa
L Verrest, AE Kip, AM Musa, GJ Schoone, HDFH Schallig, J Mbui, ...Clinical Infectious Diseases 73 (5), 775-782, 2021202
13
2021
Smear microscopy for diagnosis of pulmonary tuberculosis in eastern Sudan
YA Shuaib, EAG Khalil, UE Schaible, LH Wieler, MAM Bakheit, ...Tuberculosis research and treatment 2018, 2018201
11
2018
Geographical variability in paromomycin pharmacokinetics does not explain efficacy differences between eastern african and Indian visceral leishmaniasis patients
L Verrest, M Wasunna, G Kokwaro, R Aman, AM Musa, EAG Khalil, ...Clinical Pharmacokinetics 60, 1463-1473, 2021202
9
2021
Immune response modifying effects of bee venom protein [Melittin]/Autoclaved L. donovani complex in CD1 Mice: the search for new vaccine adjuvants
WS Eltahir Saeed, EA Gasim KhalilJ Vaccines Vaccin (372), 2, 2017201
8
2017
Association of HLA‐DR‐DQ alleles, haplotypes, and diplotypes with type 1 diabetes in Saudis
N Eltayeb‐Elsheikh, E Khalil, M Mubasher, A AlJurayyan, H AlHarthi, ...Diabetes/Metabolism Research and Reviews 36 (), e3345, 2020202
8
2020
Safety and toxicity of aqueous leaf extracts of Camellia sinensis, Parquetina nigrescens and Telfairia occidentalis in mice
OL Olayinka, EAG Khalil, SA Atunwa, AA Abdullaahi, MK Salawu, ...African Journal of Pharmacy and Pharmacology 12 (1), 20-220, 20120
8
2018
Paromomycin and miltefosine combination as an alternative to treat patients with visceral leishmaniasis in eastern Africa: A randomized, controlled, multicountry trial
AM Musa, J Mbui, R Mohammed, J Olobo, K Ritmeijer, G Alcoba, ...Clinical Infectious Diseases 6 (3), e11-e1185, 2023202
7
2023
Vaccines for visceral leishmaniasis: Hopes and hurdles
EAG KhalilLeishmaniases as Re-emerging Diseases, 2018201
4
2018

Referred From: https://scholar.google.com/citations?user=OxzVOAwAAAAJ&hl=en

Cited by
Citations 6091
h-index 43
i10-index 95
Recommended Journals
Open Access Journals